Use of 81 vs 325mg of ASA in Treatment of BCVI

Launched by LONDON HEALTH SCIENCES CENTRE · Apr 18, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how different doses of aspirin (also known as ASA) can help treat blunt cerebrovascular injury (BCVI), which is damage to the blood vessels in the neck that can happen after a serious injury. BCVI can lead to strokes in some patients if not treated quickly, so finding the best treatment is very important. The trial will compare two doses of aspirin: 81 mg and 325 mg, to see which one is more effective at preventing strokes while also causing fewer bleeding problems.

To participate in this study, you must be at least 18 years old and have been diagnosed with BCVI using a specific imaging test within three days of your injury at a major trauma center. Unfortunately, if you have certain conditions, such as being pregnant, having pre-existing blood vessel diseases, or needing immediate surgery, you won’t be eligible. If you join the trial, you can expect to take one of the two doses of aspirin and be monitored for any signs of stroke or bleeding complications. This research aims to help determine the best treatment options for future patients with BCVI.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients ≥ 18 years of age
• • Diagnosed with BCVI via CT angiography (CTA) within 72 hours of injury at a Level I Trauma Center
• Exclusion Criteria:
• • 1. ≤18 years old
• • 2. Known Pregnancy
• • 3. Diagnosis of BCVI made based on imaging from another hospital (non-LTH)
• • 4. Known pre-existing carotid/vertebral artery disease
• • 5. Stroke on presentation/before BCVI diagnosis
• • 6. Determined to require immediate surgical or interventional management of BCVI
• • 7. Known allergy to ASA
• • 8. Unable to consent OR absence of a Substitute Decision Maker (SDM)